Table 6.
Comparison of studies evaluating the incidence and the prognostic significance of neoplastic involvement of para-aortic lymph nodes
| Author, year of publication | Tumour histology | Type of para-aortic dissection | No. of metastatic para-aortic nodes (%) | Survival | Strategy recommended |
|---|---|---|---|---|---|
| Kayahara M, 199815 | PDAC | Not reported | 18 (18.2) | Not evaluable | Not reported |
| Yoshida T, 199821 | Cholangiocarcinoma | Not reported | 5 (25) | Not reported | Not reported |
| Yoshida T, 200423 | Peri-ampullary tumours | Not reported | 15 (15) | 1-year survival: 33% | Contraindication to PD |
| 2-year survival: 27% | |||||
| 3-year survival: 0% | |||||
| Mean survival 14.7 months | |||||
| Shimada K, 200616 | PDAC | Not reported | 27 (19.8) | Median OS: 13 months | Contraindication to PD |
| Doi R, 200717 | PDAC | 16a2 + 16b1 | 19 (14.3) | Median OS: 5.1 months | Contraindication to PD |
| 1-year survival: 16% | |||||
| Yamada S, 200918 | PDAC | Not reported | 48 (8.9) | Median OS: 8.0 months | Indication to PD |
| Yamada S, 200922 | PDAC | Not reported | 45 (13.4) | Median OS: 7.8 months | Not absolute contraindication to PD |
| Murakami Y, 201120 | Cholangiocarcinoma | 16a2 + 16b1 | 17 (15) | 5-year survival: 24% | Indication to PD |
| Schwarz L, 201419 | PDAC | 16b1 | 17 (15.3) | Median OS: 15.7 months | Contraindication to PD |
| Median DFS: 8.4 months | |||||
| Current study, 2015 | Peri-ampullary tumours and PDAC | 16a2 + 16b1 | 15 (11.1) | Mean OS (periampullary): 32 months | Indication to PD |
| Median OS (PDAC): 18 |
PDAC, pancreatic ductal adenocarcinoma; OS, overall survival.